Additionally, isocitrate dehydrogenase (IDH) mutations have been employed as significant prognostic biomarkers as there is documented favorable outcomes for patients with mutated IDH (IDHmut) with their survival span longer than glioma patients with wild‐type IDH (IDHwt) [1, 4]. Here, IDH1 is linked to glioma.